Is There a Better Therapeutic Time Window from Diagnosis to Treatment for Elderly Acute Myeloid Leukemia Patients Receiving Hypomethylating Agents?
作者信息
Molica Matteo, Maurillo Luca, Rossi Marco, Breccia Massimo, Mazzone Carla, de Fabritiis Paolo, Perrone Salvatore
机构信息
Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, 88100 Catanzaro, Italy.
Department of Biomedicina e Prevenzione, Tor Vergata University, 00133 Rome, Italy.
出版信息
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024055. doi: 10.4084/MJHID.2024.055. eCollection 2024.
Abstract
摘要
相似文献
1
Is There a Better Therapeutic Time Window from Diagnosis to Treatment for Elderly Acute Myeloid Leukemia Patients Receiving Hypomethylating Agents?
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024055. doi: 10.4084/MJHID.2024.055. eCollection 2024.
2
Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.
Haematologica. 2020 Jan 31;105(2):398-406. doi: 10.3324/haematol.2018.208637. Print 2020.
3
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Cancer Med. 2023 May;12(10):11838-11848. doi: 10.1002/cam4.5858. Epub 2023 Mar 31.
4
Hypomethylating Agents for Treatment of Elderly Patients with Refractory Acute Myeloid Leukemia - A Case Report with a Focused Review of Literature.
Cureus. 2018 Jun 5;10(6):e2734. doi: 10.7759/cureus.2734.
5
Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
Ann Hematol. 2017 Nov;96(11):1801-1809. doi: 10.1007/s00277-017-3104-9. Epub 2017 Aug 21.
6
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.
Biol Blood Marrow Transplant. 2016 Jan;22(1):47-53. doi: 10.1016/j.bbmt.2015.08.031. Epub 2015 Sep 4.
7
[New Drugs in the Treatment of Acute Myeloid Leukemia in the Elderly].
Klin Onkol. 2017 Summer;30(3):190-196. doi: 10.14735/amko2017190.
8
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.
9
The role of hypomethylating agents in the treatment of elderly patients with AML.
J Geriatr Oncol. 2014 Jan;5(1):89-105. doi: 10.1016/j.jgo.2013.08.004. Epub 2013 Sep 24.
10
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents.
Leuk Lymphoma. 2023 Nov-Dec;64(11):1840-1846. doi: 10.1080/10428194.2023.2239407. Epub 2023 Aug 8.
本文引用的文献
1
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours.
Expert Rev Hematol. 2022 Nov;15(11):973-986. doi: 10.1080/17474086.2022.2140137. Epub 2022 Nov 3.
2
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.
Cancers (Basel). 2022 Oct 6;14(19):4897. doi: 10.3390/cancers14194897.
3
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Blood. 2022 Nov 24;140(21):2228-2247. doi: 10.1182/blood.2022015853.
4
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
5
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
6
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood. 2020 Aug 13;136(7):823-830. doi: 10.1182/blood.2019004583.
7
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
8
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16.
Zotero 插件